Received Aug 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Injection site redness; Injection site itching; This non-serious case was reported by a consumer and described the occurrence of injection site erythema in a 59-year-old female patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On 29-JUL-2025, the patient received Shingles vaccine. On 29-JUL-2025, less than a day after receiving Shingles vaccine, the patient experienced injection site erythema (Verbatim: Injection site redness) and injection site itching (Verbatim: Injection site itching). The outcome of the injection site erythema and injection site itching were resolving. It was unknown if the reporter considered the injection site erythema and injection site itching to be related to Shingles vaccine. It was unknown if the company considered the injection site erythema and injection site itching to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 03-AUG-2025 The patient received the shingles vaccine and experienced itching and redness at injection site